Fibrates reduce triacylglycerol content by upregulating adipose triglyceride lipase in the liver of rats

Journal of Pharmacological Sciences

Volumn 123, Issue 4, 2013, Pages 356-370

  Karahashi, Minako ^a   Hoshina, Miki ^a   Yamazaki, Tohru ^a   Sakamoto, Takeshi ^a   Mitsumoto, Atsushi ^b   Kawashima, Yoichi ^a   Kudo, Naomi ^a  

^a JOSAI UNIVERSITY   (Japan)

^b JOSAI INTERNATIONAL UNIVERSITY   (Japan)

Author keywords

Adipose triglyceride lipase; Fibrate; Fibric acid; Rat liver; Triacylglycerol

Indexed keywords

BEZAFIBRATE; CLOFIBRIC ACID; FENOFIBRATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE;

ADIPOSE TISSUE; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIETARY INTAKE; ENZYME ACTIVITY; FATTY ACID OXIDATION; GENE; GENE EXPRESSION; IN VIVO STUDY; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIPID DEGRADATION; LIPID LIVER LEVEL; LIPOGENESIS; MALE; NONHUMAN; RAT; UPREGULATION;

ANIMALS; BEZAFIBRATE; CLOFIBRIC ACID; FATTY LIVER; FENOFIBRATE; LIPASE; LIPID PEROXIDATION; LIVER; MALE; MOLECULAR TARGETED THERAPY; PPAR ALPHA; RATS; RATS, WISTAR; TRIGLYCERIDES; UP-REGULATION;

EID: 84892654182     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.13149FP     Document Type: Article

References (49)

1. Berger J, Wagner JA. Physiological and therapeutic roles of peroxisome proliferator-activated receptors. Diabetes Technol. Ther. 2002;4:163-174.
2. Kersten S. Peroxisome proliferator activated receptors and lipoprotein metabolism. PPAR Res. 2008;2008:132960.
3. Barter PJ, Rye K-A. Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Arterioscler Thromb Vasc Biol. 2008;28:39-46.
4. Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010;375:1875-1884.
5. Wilding JPH. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes. Diabetes Obese Metab. 2012;14:973-982.
6. Guerre-Millo M, Gervois P, Raspé E, Madsen L, Poulain P, Derudas B, et al. Peroxisome proliferator-activated receptor α activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000;275:16638-16642.
7. Chatrath H, Vuppalanchi R, Chalasani N. Dislipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis. 2012;32:22-29.
8. Nseir W, Mograbi J, Ghali M. Lipid-lowering agents in non-alcoholic fatty liver disease and steatohepatitis: Human studies. Dig Dis Sci. 2012;57:1773-1781.
9. Zimmermann R, Strauss JG, Haemmerle G, Schoiswohl G, Birner-Gruenberger R, Riederer M, et al. Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase. Science. 2004;306:1383-1386.
10. Zimmermann R, Lass A, Haemmerle G, Zechner R. Fate of fat: the role of adipose triglyceride lipase in lipolysis. Biochim Biophys Acta. 2009;1791:494-500.
11. Ong KT, Mashek MT, Bu SY, Greenberg AS, Mashek DG. Adipose triglyceride lipase is a major hepatic lipase that regulates triacylglycerol turnover and fatty acid signaling and partitioning. Hepatology. 2011;53:116-126.
12. Wu JW, Wang SP, Alvarez F, Casavant S, Gauthier N, Abed L, et al. Deficiency of liver adipose triglyceride lipase in mice causes progressive hepatic steatosis. Hepatology. 2011;54:122-132.
13. Turpin SM, Hoy AJ, Brown RD, Rudaz CG, Honeyman J, Matzaris M, et al. Adipose triacylglycerol lipase is a major regulator of hepatic lipid metabolism but not insulin sensitivity in mice. Diabetologia. 2011;54:146-156.
14. Reid NB, Ables GP, Otlivanchik OA, Schoiswohl G, Zechner R, Blaner WS, et al. Hepatic overexpression of hormone-sensitive lipase and adipose triglyceride lipase promotes fatty acid oxidation, stimulates direct release of free fatty acids, and ameliorates steatosis. J Biol Chem. 2008;283:13087-13099.
15. Fruchart JC, Duriez P. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs Today. 2006;42:39-64.
16. Heald M, Cawthorne MA. Dual acting and pan-PPAR activators as potential anti-diabetic therapies. In: Schwanstecher M, editor. Diabets - perspectives in drug therapy. Handbook of Experimental Pharmacology. Heidelberg: Springer; 2011;203:35-51.
17. Goldenberg I, Benderly M, Goldbourt U. Update on the use of fibrates: focus on bezafibrate. Vasc Health Risk Manag. 2008;4:131-141.
18. Imai K, Koyama M, Kudo N, Shirahata A, Kawashima Y. Increase in hepatic content of oleic acid induced by dehydroepiandrosterone in the rat. Biochem Pharmacol. 1999;58:925-933.
19. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37:911-917.
20. Karahashi M, Fukuhara H, Hoshina M, Sakamoto T, Yamazaki T, Mitsumoto A, et al. A simple and sensitive method for the determination of fibric acids in the liver by liquid chromatography. Biol Pham Bull. In press.
21. Karahashi M, Ishii F, Yamazaki T, Imai K, Mitsumoto A, Kawashima Y, et al. Up-regulation of stearoyl-CoA desaturase 1 increases liver MUFA content in obese Zucker but not Goto-Kakizaki rats. Lipids. 2013;48:457-467.
22. Soni KG, Mardones GA, Sougrat R, Smirnova E, Jackson CL, Bonifacino JS. Coatomer-dependent protein delivery to lipid droplets. J Cell Sci. 2009;122:1834-1841.
23. Holm C, Østerlund T. Hormone-sensitive lipase and neutral cholestery ester lipase. Methods Mol Biol. 1999;109:109-121.
24. Chen W-L, Chen Y-L, Chiang Y-M, Wang S-G, Lee H-M. Fenofibrate lowers lipid accumulation in myotubes by modulating the PPARα/AMPK/FoxO1/ATGL pathway. Biochem Pharmacol. 2012;84:522-531.
25. Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. J Med Chem. 2000;43:527-550.
26. Cornwell PD, De Souza AT, Ulrich RG. Profiling of hepatic gene expression in rats treated with fibric acid analogs. Muat Res. 2004;549:131-145.
27. Akkaoui M, Cohen I, Esnous C, Lenoir V, Sournac M, Girard J, et al. Modulation of the hepatic malonyl-CoA-carnitine palmitoyltransferase 1A partnership creates a metabolic switch allowing oxidation of de novo fatty acids. Biochem J. 2009;420:429-438.
28. Mannaerts GP, Debeer LJ, Thomas J, De Schepper PJ. Mitochondrial and peroxisomal fatty acid oxidation in liver homogenates and isolated hepatocytes from control and clofibrate-treated rats. J Biol Chem. 1979;254:4585-4595.
29. McGarry JD, Brown NF. The Mitochondrial carnitine palmitoyltransferase system - from concept to molecular analysis. Eur J Biochem. 1997;244:1-14.
30. Stefanovic-Racic M, Perdomo G, Mantell BS, Sipula IJ, Brown NF, O'Doherty RM. A moderate increase in carnitine palmitoyltransferase 1a activity is sufficient to substantially reduce hepatic triglyceride levels. Am J Physiol Endocrinol Metab. 2008;294:E969-E977.
31. Lankester DL, Brown AM, Zammit VA. Use of cytosolic triacylglycerol hydrolysis products and of exogenous fatty acid for the synthesis of triacylglycerol secreted by cultured rat hepatocytes. J Lipid Res. 1998;39:1889-1895.
32. Glatz JFC, Luiken JJFP, Bonen A. Membrane fatty acid transporters as regulators of lipid metabolism: implications for metabolic disease. Physiol Rev. 2010;90:367-417.
33. Poppelreuther M, Rudolph B, Du C, Großmann R, Becker M, Thiele C, et al. The N-terminal region of acyl-CoA synthetase 3 is essential for both the localization on lipid droplets and the function in fatty acid uptake. J Lipid Res. 2012;53:888-900.
34. Yamazaki T, Okada H, Sakamoto T, Sunaga K, Tsuda T, Mitsumoto A, et al. Differential induction of stearoyl-CoA desaturase 1 and 2 genes by fibrates in the liver of rats. Biol Pharm Bull. 2012;35:116-120.
35. Kawashima Y, Kozuka H. Regulation of palmitoyl-CoA chain elongation and linoleoyl-CoA elongation in rat liver microsomes and the differential effects of peroxisome proliferators, insulin and thyroid hormone. Biochim Biophys Acta. 1985;834:118-123.
36. Kawashima Y, Kozuka H. Increased activity of stearoyl-CoA desaturation in liver from rat fed clofibric acid. Biochim Biophys Acta. 1982;713:622-628.
37. Hirose A, Yamazaki T, Sakamoto T, Sunaga K, Tsuda T, Mitsumoto A, et al. Clofibric acid increases the formation of oleic acid in endoplasmic reticulum of the liver of rats. J Pharmacol Sci. 2011;116:362-372.
38. Man WC, Miyazaki M, Chu K, Ntambi J. Colocalization of SCD1 and DGAT2: implying preference for endogenous monounsaturated fatty acids in triglyceride synthesis. J Lipid Res. 2006;47:1928-1939.
39. Miyazak M, Kim Y-C, Ntambi JM. A lipogenic diet in mice with a disruption of the stearoyl-CoA desaturase 1 gene reveals a stringent requirement of endogenous monounsaturated fatty acids for triglyceride synthesis. J Lipid Res. 2001;42:1018-1024.
40. Listenberger LL, Han X, Lewis SE, Cases S, Farese RV, Ory DS, et al. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad Sci U S A. 2003;100:3077-3082.
41. Rakhshandehroo M, Sanderson LM, Matilainen M, Stienstra R, Carlberg C, de Groot PJ, et al. Comprehensive analysis of PPARα-dependent regulation of hepatic lipid metabolism by expression profiling. PPAR Res. 2007;2007:26839.
42. Huhtinen K, O'Byrne J, Lindquist PJG, Contreras JA, Alexson SEH. The peroxisome proliferator-induced cytosolic type I acyl-CoA thioesterase (CTE-I) is a serine-histidine-aspartic acid α/β hydrolase. J Biol Chem. 2002;277:3424-3432.
43. Dongol B, Shah Y, Kim I, Gonzalez FJ, Hunt MC. The acyl-CoA thioesterase I is regulated by PPARα and HNF4α via a distal response element in the promoter. J Lipid Res. 2007;48:1781-1791.
44. Kawashima Y, Katoh H, Kozuka H. Sex-related difference in the effect of clofibric acid on induction of two novel long-chain acyl-CoA hydrolases in rat liver. Biochim Biophys Acta. 1982;712:48-56.
45. Sapiro JM, Mashek MT, Greenberg AS, Mashek DG. Hepatic triacylglycerol hydrolysis regulates peroxisome proliferator-activated receptor α activity. J Lipid Res. 2009;50:1621-1629.
46. Furuhashi M, Hotamisligil GS. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov. 2008;7:489-503.
47. Nakagawa S, Kawashima Y, Hirose A, Kozuka H. Regulation of hepatic level of fatty-acid-binding protein by hormones and clofibric acid in the rat. Biochem J. 1994;297:581-584.
48. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. Proc Natl Acad Sci U S A. 1997;94:4312-4317.
49. Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS, et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ. Proc Natl Acad Sci U S A. 1997;94:4318-4323.